Subscribe to The Free Market Chronicle and join the 2,713 subscribers getting it for FREE!
Why Biotech May Outperform In 2018 – Premium Content
Biotech May Outperform in 2018 from Michael Kramer on Vimeo.
Michael Kramer and the Clients of Mott Capital own shares of $ACAD
Mott Capital Management, LLCย is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein.ย Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.
ยฉ 2017 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.
Tags: #biotech #2018 #outperform